In-house ownership and securing rights to developed intellectual property in key regions
First written in FY2017. 3 of 6 entries say "Restated". Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「In autumn 2024, we also obtained a new U.S. patent covering cell therapy using SB623 for chronic-stage cerebral infarction, substantially extending the term of SB623’s indication patent in the United States, our largest market.」
The company obtained a new U.S. patent covering the use of SB623 for chronic-stage cerebral infarction in autumn 2024, demonstrating concrete progress in securing rights and extending the term of the U.S. indication patent. - FY2023RestatedAnnual report
「Our Group basically holds all patents for the regenerative cell therapies under development, SB623, SB618, SB308, MSC1 and MSC2.」
The policy of principally holding the intellectual property for SB623, SB618, SB308, MSC1 and MSC2 internally and obtaining rights in key regions has been reaffirmed. - FY2022RaisedAnnual report
「Our Group basically holds all patents for the regenerative cell therapies under development, SB623, SB618, SB308, MSC1 and MSC2.」
The scope of the intellectual property principally held internally has expanded from SB623, SB618 and SB308 to 5 regenerative cell therapies, including MSC1 and MSC2. The company also described obtaining rights in key regions. - FY2020RestatedAnnual report
「Our basic policy is to obtain all intellectual property required to develop regenerative cell therapies itself, and all core patents for the regenerative cell therapies under development, SB623, SB618 and SB308, have already been obtained.」
The policy of retaining development intellectual property internally and obtaining rights in key regions has been reaffirmed. - FY2019RestatedAnnual report
「To maximize revenue from development and product sales, our Group’s basic policy is to obtain all intellectual property required to develop regenerative cell therapies itself. It has already obtained all core patents for the regenerative cell therapies under development, SB623, SB618 and SB308.」
The policy of obtaining and holding the intellectual property for SB623, SB618 and SB308 internally, and the explanation that their core patents have already been obtained, have been reaffirmed. - FY2017First statedAnnual report
「To maximize revenue from development and product sales, our Group’s basic policy is to obtain all intellectual property required to develop regenerative cell therapies itself. It has already obtained all core patents for the regenerative cell therapies under development, SB623, SB618 and SB308.」
The policy of obtaining in-house the intellectual property required to develop SB623, SB618 and SB308, and the fact that their core patents have already been obtained, have been disclosed.